Utility of measuring serum levels of anti‐PGL‐I antibody, neopterin and C‐reactive protein in monitoring leprosy patients during multi‐drug treatment and reactions

Abstract

Measuring the serum levels of PGL-I antibodies and neopterin appeared to be useful in distinguishing MB from PB patients, whereas monitoring the levels of PGL-I antibodies appeared to be useful in monitoring MB patients on MDT. Measuring serum CRP, although not useful in monitoring the patients, has limited significance in detecting ENL reactional patients.